Why did Allakos (ALLK) stock crash today?

Follow us on Google News:
 Why did Allakos (ALLK) stock crash today?
Image source: myboys.me,Shutterstock

Highlights

  • Allokos said that its lirentelimab treatment failed to meet the endpoints in clinical studies.

  • The stocks were down 89.87% but climbed up from Tuesday’s close by 11.46% in afterhours.

  • CEO Robert Alexander said the research team was “deeply disappointed” over the results.

Shares of Allakos (NASDAQ: ALLK) nosedived nearly 90% at the close on Wednesday after presenting its clinical study data for the drug lirentelimab used in treating gastrointestinal diseases.

However, the shares recovered some lost grounds in the aftermarket session. The stocks were down 89.87% to US$8.55 but climbed up from Tuesday’s close by 11.46% to US$9.53 in afterhours trading.

The crash came after the company announced the results from its “Phase 3 Enigma 2 and Phase 2/3 Kryptos clinical studies” to assess lirentelimab, which failed to meet the co-primary endpoints.

Allakos said that although the studies met their histologic co-primary endpoints, neither could show an improvement on “patient-reported symptomatic co-primary endpoints”.

The poor results led to the stock’s free fall.

In the Enigma 2 study, patients who received a placebo reported a “greater change in the six-symptom total symptom score (TSS) than those who received lirentelimab.

Likewise, in the Kryptos study, those who received a higher dose of lirentelimab showed improvement in symptoms than those on a placebo, but it wasn't enough from a statistical standpoint.

CEO Robert Alexander said the research team was “deeply disappointed” over the results. He said the studies did not “achieve the symptomatic endpoints".

Allakos’ chief medical officer Craig Paterson called the results "disappointing".

Also Read: Pfizer gets FDA greenlight for first Covid-19 pill Paxlovid

Shares of Allakos (NASDAQ: ALLK) nosedived nearly 90% at the close on Wednesday.

Source: Pixabay

Also Read: Justworks IPO: Why investors exuded confidence in HR tech startup?

What’s Next

Medical officer Craig Paterson said the company will continue to analyze the data from the studies to find a way forward for lirentelimab. Allakos also plans to continue its research on a subcutaneous version of the drug for treating atopic dermatitis, asthma, and chronic urticaria.

Stock Performance

The Allakos stock’s 52-week highest price was US$157.98, and the lowest price was US$70.37.

Its current market capitalization is about US$464 million. Its forward P/E one year is -18.84, and the EPS is US$-4.13.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.

Featured Articles